ClinicalTrials.Veeva

Menu

Chemical and Mechanical Angioplasty for Vasospasm (SAVEBRAIN)

F

Free University of Brussels (ULB)

Status

Completed

Conditions

Arteriovenous Malformations, Cerebral
Ruptured Cerebral Aneurysm
Aneurysmal Subarachnoid Hemorrhage
Vasospasm, Intracranial
Arteriovenous Fistula
Stenosis

Treatments

Procedure: Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis

Study type

Interventional

Funder types

Other

Identifiers

NCT05268445
SRB2021297

Details and patient eligibility

About

This is a monocentric randomized prospective trial comparing 2 different endovascular strategies of intracranial arterial angioplasty in case of refractory intracranial arterial vasospastic stenosis :

  • chemical angioplasty
  • chemical and mechanical angioplasty

Full description

Compare in a randomized prospective trial 2 approved treatments of refractory intracranial arterial vasospastic stenosis, chemical angioplasty versus chemical and mechanical angioplasty, using devices already used in clinical practice and CE marked: chemical angioplasty using Nimotop versus chemical and mechanical angioplasty with balloon or adjustable remodeling mesh on brain perfusion evaluated by brain computed tomography (CT) Perfusion

Nowadays, the choice between chemical or chemical and mechanical angioplasty depends on the neurointerventionist for each procedure, no difference in efficiency or safety has been proved and no solid scientific data helps the physician in choosing the correct treatment for each patient.

Enrollment

22 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 years.
  2. Non-traumatic intracranial hemorrhage (ruptured aneurysm, AVM, or per-procedural complication etc)
  3. Ruptured aneurysm, AVM, intracranial arterial perforation or any bleeding lesion secured with surgical clipping or endovascular intervention.
  4. No contra-indication to both CTP and MRI imaging
  5. Subject or legal representative is able and willing to give informed consent.
  6. Refractory of intracranial arterial vasospastic stenosis requiring an endovascular angioplasty with a severe stenosis defined on CTA or DSA; and/or a significant hypoperfusion defined according to the mismatch profile in stroke or a MTT>6 seconds. The volume of critically hypoperfused tissue will be based on a time to maximum of the tissue residue function (Tmax) threshold of >6 sec using the Rapid (or equivalent) software.

Exclusion criteria

  1. Angioplasty by one of the two methods considered as impossible or too risky by the neurointerventionist
  2. Inability to obtain consent from patient or patients relatives
  3. Pregnant women
  4. Less than 18 years of age
  5. Need to use any other device
  6. Vertebro-basilar arteries will not be randomized because of the difficulty to assess the perfusion volume in this territory, but will be treated if necessary according to our local protocol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

22 participants in 2 patient groups

Chemical angioplasty
Active Comparator group
Description:
Chemical angioplasty using intra-arterial Nimodipin
Treatment:
Procedure: Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
Chemical and Mechanical angioplasty
Active Comparator group
Description:
Balloon angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Neurospeed balloon) or Adjustable remodeling mesh angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Comaneci) in association with intra-arterial Nimodipin
Treatment:
Procedure: Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis

Trial contacts and locations

1

Loading...

Central trial contact

CUB-Hôpital Erasme Service de la Recherche biomédicale; Boris Lubicz, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems